Novo Nordisk in $1.3 billion deal to buy hypertension drug
COPENHAGEN Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular
1970-01-01 08:00
Singapore Exchange revises IPO rules for life science firms
SINGAPORE Singapore Exchange Ltd (SGX) is amending its initial public offering (IPO) rules to clarify that life science
1970-01-01 08:00